Pasithea Therapeutics Corp.
KTTA · Healthcare · $15M
After-hours $0.46-5.92%
Price
$0.57
$0.49
Jul 1, 26Sep 29, 26
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
RevenueOperating IncomeNet Income
9/'26
Revenue$0M
6/'26 vs prev quarter
Company Health
Market Cap$15M
Cash on Hand$45.7B296439.9% of market cap
Free Cash Flow$-9.5B-61691.7% of market cap
Short Float 0.9% · biweekly · settled 26.09.15
Among 463 Biotechnology peers
LowMedianHigh
PBR0.0xmedian 2.0xROE-0.0%median -54.5%Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis ConferenceSep 14
Pasithea Therapeutics Announces Participation in Two September 2026 Investor ConferencesSep 3
Reviewing Oncobiologics (NASDAQ:OTLK) and Pasithea Therapeutics (NASDAQ:KTTA)Aug 12
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026Jul 21
Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision SummitJul 8
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol ExpansionJun 30
